# MEDICINE **TCM cancer treatment** enters final trials in US

#### By SHAN JUAN shanjuan@chinadaily.com.cn

A traditional Chinese medicine preparation used to treat cancer and boost patients' immunity has been given the go-ahead for a third phase of clinical trials in the US, the last major hurdle for those wishing to launch new drugs in the US market.

The drug, known as Kanglaite Injection, contains anticancer compounds extracted from the seed of coix, a grasslike relative of maize, and has been approved and used as a cancer treatment in China since 1995.

It has been used by more than 200,000 patients and is among the best-selling cancer treatments in the country.

Its inventor, Li Dapeng, has been seeking registration for the drug in the United States. The US Food and Drug Administration gave the go-ahead for clinical trials in 2001. Kangalite is the first TCM injection treat-

ment to undergo the FDA approval process.

"After promising results from the Phase 2 clinical trials, they are permitting us to move on to the third and final phase, where a larger number of volunteer cancer patients will be involved," Li said. "If everything goes smoothly, KLT will hit the US market in three years." In the second phase of trials,

the natural herbal remedy exceeded the success rate of Western cancer treatments, prolonging patients' lives by 1.9 months with fewer side effects. Li described the US approv-

al procedure as long and costly, but said it would be worth the effort if it helps to bring TCM to patients worldwide. It has taken 16 years and the expenditure of millions of yuan to reach the phase three

clinical trials stage. Li is an academic at the Chinese Academy of Engineering and a researcher at Zhejiang Chinese Medical University. Yu Wenming, deputy director of the State Administration of TCM, said the government will encourage the spread of more TCM products and services abroad to improve people's health worldwide. TCM remedies that have

already been recognized in the West include the asthma treatment Mahuang, also known as Ephedra sinica, and Qinghao, or Artemisia annua, used to treat malaria.

It is difficult to get approval in the West for TCM treatments because of differences in standards, according to TCM expert Zhang Boli of the academy. "TCM has to learn their

rules to become globalized, as people overseas also need this time-honored form of medicine," he said. "TCM has an efficacy prov-

en by time and experience, while the effectiveness of Western medicine is largely lab and evidence based." Zhang called for more gov-

ernment support for Chinese TCM producers.



#### Home wet home

A student salvages some of his possessions in his flooded room at Nanjing University of Science and Technology in Jiangsu province on Sunday after torrential rains lashed the city. YANG BO / FOR CHINA DAILY

let trains, expecting speeds of

500 km/h. Trials were under-

taken on several trains in

Jia Limin of Beijing Jiao-

tong University, who heads

China's high-speed railway

innovation program, said that

if everything goes well, trains

equipped with the new trac-

October.

#### TRANSPORTATION

# China joins global elite in fast rail

#### By ZHAO LEI

zhaolei@chinadaily.com.cn

China has become a world leader in high-speed railway technology with its development of a cutting-edge permanent magnet synchronous traction system that will take bullet trains to an ultrafast 500 kilometers per hour.

The advanced 690-kilowatt traction system was developed by CRRC Corp, the country's

train-making behemoth, at its Zhuzhou Institute in Hunan province. It will soon enter mass production, said Ding Rongjun, a member of the Chinese Academy of Engineering who heads the institute.

"Now we have our own permanent magnet synchronous traction system with full intellectual property rights, marking a new chapter in China's high-speed railways," he said, adding that only a handful of

countries are capable of manufacturing the sophisticated apparatus, including Germany and Japan.

Feng Jianghua, deputy director of the institute, said the adoption of the technology will reshape the high-speed railway industry because traction equipment is the most important part of a bullet train. Currently, most high-speed

trains in service in the world are propelled by alternating current asynchronous motors, a traction system first developed in the 1970s.

The Zhuzhou Institute began research and development on permanent magnet synchronous traction technology in 2003 after it noticed that major international train makers, such as Siemens and Bombardier, had launched projects to acquire the equipment, Feng told China Economic Weekly.

The magazine quoted Xu 500 Junfeng, a senior engineer at the institute, as saying that km per hour engineers overcame a large number of technical difficul-Speed of bullet trains operating ties. China had never looked at on CRRC Corp's advanced 690 the high-tech equipment kilowatt traction system before the project. After eight years, engineers

completed development in 2011 and installed the advanced traction system on trains running on Subway Line 2 in Shenyang, Liaoning province, as a trial.

The test has proved successful, Xu said.

In December 2013, the institute brought the system to bul-

#### tion system will become fully operational by 2018.

Compared with an alternating current asynchronous motor, the new system boasts more power, simpler configuration and lower electrical consumption, Jia said.

"The new system has fewer parts than the current traction apparatus, so it is more reliable and efficient," he said.

Sheng Guangzu, general manager of China Railway Corp, has pledged to speed up the development of key technologies in high-speed rail and to design a new bullet train using Chinese standards.

International Education Column If you are interested in our special education column, please contact: i.education@chinadaily.com.cn

CHICAGO BOOTH 🐻 **Master of Finance** in Beijing INQUIRY. INSIGHT. IMPACT. **YOU BELONG AT** MISSOURI STATE UNIVERSITY A partnership with Renmin University THE CHICAGO \* Quality academic programs with high accreditations More than 1,400 international students on our friendly, safe campus in Springfield, Missouri APPROACH.  $\boldsymbol{\ast}$  Established presence in China thanks to branch campus in Dalian and partnerships with other Chinese institutions Recent honors: Named to America's Top Colleges list by Forbes magazine; received Best Midwestern distinction from The Princeton Review HONG KONG Earn a world-class master's degree in finance, International students have memorable experiences, from campus involvement to travel around U.S. while you work. \* Unbeatable value with scholarships and internships for international students ADDRESS. This English-language program provides an exceptional opportunity to earn a www.missouristate.edu master's degree in finance from Canada's Queen's School of Business - one of the world's premier business schools. Weekend classes allow you to complete The Chicago Booth Executive MBA. ige courses and more: www. ristate.edu/futurestudents




the program while you continue to work, right here in Beijing.

Find out more at qsb.ca/mfin\_beijing f Ƴ in CFA Program Partner of CFA Institute



CHICAGO LONDON SINGAPORE HONG KONG





Missouri State.



Its 133 hectares of leafy space, lakes, playing pitches, historic and modern buildings is home to Ireland's largest community of students, faculty and researchers. Located in the Embassy belt of Dublin, one of Europe's most vibrant cities, the safe modern campus has a warm welcome for every visitor



University College Dublin

Email: chinaoffice@ucd.ie 🌐 www.ucd.ie/international

### University of South Wales

## **Professional courses** for a professional world



We offer professionally-oriented undergraduate and postgraduate courses in a range of areas including:

- Business Engineering Aircraft Maintenance Law
- Accounting Finance Project Management Computing
- TESOL Built Environment Nursing Education

Art and Design

#### www.southwales.ac.uk/international



\*Terms and conditions apply.